News

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter

Pharmaceutical Technology\'s In the Lab eNewsletter-06-03-2020
Volume15
Issue 6
Pages: 44–45,58

New SARS-CoV-2 Molecular Quality Control

The quality control from ZeptoMetrix is formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable.

On May 5, 2020, ZeptoMetrix announced its new, ready-to-use NATtrol, a SARS-CoV-2 molecular quality control for laboratory QC and test validation.

According to a company press release, the quality control is formulated with purified intact viral particles that have been chemically modified to render them non-infectious and refrigerator stable, including:

  • NATtrol SARS-CoV-2 Positive Control

  • Product Number: NATSARS(COV2)-ERC

Complementing the release of the positive control is a negative control formulated with human A549 cells:

  • NATtrol SARS-CoV-2 Negative Control

  • Product Number: NATSARS(COV2)-NEG

"Due to the unprecedented COVID-19 pandemic, we were tasked to develop and deploy reliable, user-friendly commercial solutions for ready-to-use, non-infectious SARS-CoV-2 full process molecular quality controls under accelerated timelines,” said Shawn R. Smith, president and CEO of ZeptoMetrix, in the press release. “Today, I am extremely proud to announce that ZeptoMetrix has launched such controls - containing purified intact viral particles of actual SARS-CoV-2 that provide laboratories, hospitals and research facilities with essential external run controls to help ensure the reliability of COVID-19 testing.”

Source: ZeptoMetrix

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx